Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee

Table 3 Secondary endpoints in patients with inflammatory osteoarthritis of the knee who received open-label adalimumab

	Baseline	4 weeks	8 weeks	12 weeks^a	22 weeks^b
Patient global	60.6 (22.0)	49.7 (22.1)**	37.4 (22.6)*	36.1 (21.9)*	44.4 (22.5)
Physician global	69.7 (12.7)	44.6 (17.8)*	34.5 (16.9)*	40.7 (22.0)*	40.1 (25.3)
Activity impairment	6.30 (1.17)	5.70 (1.53)	4.90 (1.59)**	5.10 (2.00)*	5.19 (1.80)
Sleep impairment	2.90 (0.64)	2.35 (0.81)	2.10 (0.72)**	2.05 (0.89)**	2.50 (0.73)
Target joint tenderness	1.75 (0.44)	1.00 (0.73)	0.95 (0.69)**	0.95 (0.94)**	0.81 (75)
Target joint swelling	2.15 (0.37)	1.45 (0.89)**	1.00 (1.03)*	1.15 (1.14)**	0.75 (0.77)

Mean (standard deviation) values for secondary endpoints over 22 weeks in 20 patients with inflammatory osteoarthritis of the knee who received open-label adalimumab for 12 weeks. ^aWeek 12 data versus baseline according to paired t test using last-observation-carried-forward data. ^bWeek 22 data are based on 16 patients who attended for assessment. *P < 0.0001, **P < 0.05.

ISSN: 1478-6362